Education
About Us
Working with TipRanks
Follow Us
Rocket Pharma (DE:9IP1)
:9IP1
RESEARCH TOOLSreports
9IP1 Analyst Ratings
Moderate Buy
9 Buy
8 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
9IP1 Stock 12 Month Forecast
Average Price Target
€8.26
▲(211.69%Upside)
| Highest Price Target€25.55 | Average Price Target€8.26 | Lowest Price Target€1.70 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
LifeSci Capital
€7.64
Buy
188.43%
Upside
Reiterated
07/24/25
Needham
―
Hold
―
Reiterated
07/24/25
Wedbush
€13.59
Buy
412.77%
Upside
Reiterated
07/17/25
Morgan Stanley
€5.94
Hold
124.34%
Upside
Reiterated
06/30/25
UBS
€10.19→€4.25
Buy
60.24%
Upside
Reiterated
06/17/25
Canaccord Genuity
€28.88→€9.34
Buy
252.53%
Upside
Reiterated
06/03/25
Evercore ISI
€4.25
Hold
60.24%
Upside
Reiterated
06/03/25
Bank of America Securities
€28.08→€7.64
Buy
188.43%
Upside
Reiterated
05/28/25
J.P. Morgan
€37.37→€5.94
Hold
124.34%
Upside
Downgraded
05/28/25
Jefferies
€24.63→€2.12
Hold
-19.88%
Downside
Downgraded
05/28/25
Goldman Sachs
€1.7
Sell
-35.90%
Downside
Downgraded
05/28/25
Scotiabank
€43.31→€16.14
Buy
508.92%
Upside
Reiterated
05/28/25
Leerink Partners
€31.42→€6.79
Hold
156.39%
Upside
Downgraded
05/28/25
William Blair
―
Buy
―
Reiterated
05/27/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
€7.64
Buy
188.43%
Upside
Reiterated
07/24/25
Needham
―
Hold
―
Reiterated
07/24/25
Wedbush
€13.59
Buy
412.77%
Upside
Reiterated
07/17/25
Morgan Stanley
€5.94
Hold
124.34%
Upside
Reiterated
06/30/25
UBS
€10.19→€4.25
Buy
60.24%
Upside
Reiterated
06/17/25
Canaccord Genuity
€28.88→€9.34
Buy
252.53%
Upside
Reiterated
06/03/25
Evercore ISI
€4.25
Hold
60.24%
Upside
Reiterated
06/03/25
Bank of America Securities
€28.08→€7.64
Buy
188.43%
Upside
Reiterated
05/28/25
J.P. Morgan
€37.37→€5.94
Hold
124.34%
Upside
Downgraded
05/28/25
Jefferies
€24.63→€2.12
Hold
-19.88%
Downside
Downgraded
05/28/25
Goldman Sachs
€1.7
Sell
-35.90%
Downside
Downgraded
05/28/25
Scotiabank
€43.31→€16.14
Buy
508.92%
Upside
Reiterated
05/28/25
Leerink Partners
€31.42→€6.79
Hold
156.39%
Upside
Downgraded
05/28/25
William Blair
―
Buy
―
Reiterated
05/27/25
Best Analysts Covering Rocket Pharmaceuticals
1 Month
xxx
Success Rate
14/24 ratings generated profit
Average Return
+5.79%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 58.33% of your transactions generating a profit, with an average return of +5.79% per trade.
3 Months
xxx
Success Rate
14/24 ratings generated profit
Average Return
+14.18%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +14.18% per trade.
1 Year
Success Rate
14/25 ratings generated profit
Average Return
+19.83%
reiterated a buy rating 2 days ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +19.83% per trade.
2 Years
xxx
Success Rate
3/11 ratings generated profit
Average Return
-35.23%
reiterated a xxx
rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 27.27% of your transactions generating a profit, with an average return of -35.23% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
9IP1 Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
17
15
31
31
30
Buy
2
2
5
5
5
Hold
1
1
7
9
9
Sell
0
0
1
1
1
Strong Sell
0
0
0
0
0
total
20
18
44
46
45
Each month's total comprises the sum of three months' worth of ratings.
9IP1 Financial Forecast
9IP1 Stock Forecast FAQ
What is DE:9IP1’s average 12-month price target, according to analysts?
Based on analyst ratings, Rocket Pharma’s 12-month average price target is 8.26.
What is DE:9IP1’s upside potential, based on the analysts’ average price target?
Rocket Pharma has 211.69% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Rocket Pharma a Buy, Sell or Hold?
Rocket Pharma has a consensus rating of Moderate Buy, which is based on 9 buy ratings, 8 hold ratings and 1 sell ratings.
What is Rocket Pharma’s share price target?
The average share price target for Rocket Pharma is 8.26. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €25.55 ,and the lowest forecast is €1.70. The average share price target represents 211.69% Increase from the current price of €2.65.
The highest analyst share price target is €25.55 ,and the lowest forecast is €1.70. The average share price target represents 211.69% Increase from the current price of €2.65.
What do analysts say about Rocket Pharma?
Rocket Pharma’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.
How can I buy shares of Rocket Pharma?
To buy shares of DE:9IP1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.